Clinical Trial Update: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update describing Sacituzumab tirumotecan as a monotherapy and in combination with pembrolizumab for triple-negative breast cancer, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (MK-3475) (pembrolizumab)
• Sacituzumab tirumotecan (Sac-TMT, MK-2870) (sacituzumab tirumotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Triple Negative Breast Neoplasms | Phase 3 | Status: RECRUITING